Publications by authors named "Moshe Ornstein"

Claim this Profile
M
Medical Professionals' Perceptions of and Experiences With Terminally Ill Orthodox Jewish Patients.
Moshe C Ornstein, David Harris

Am J Hosp Palliat Care· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trimodality Therapy for Bladder Cancer: A Single Institution Retrospective Analysis of Factors Associated With Outcomes for High-Risk Patients Undergoing Organ-Sparing Therapy.
Monica S Nair, Jessica Scarborough, Chandana A Reddy, Anirudh R Bommireddy, Erin Brooks, Moshe C Ornstein

Clin Genitourin Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From Challenges to Cures: Improving Outcomes in Patients With Renal Cell Carcinoma.
Moshe C Ornstein

JCO Oncol Pract· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Partial and Radical Nephrectomy for Complex Locally Advanced Renal Cell Carcinoma After Neo-Adjuvant Immune Checkpoint Inhibition: Analysis From a Phase 1b Trial (Durvalumab +/- Tremelimumab).
Jason M Scovell, Brian I Rini, Venkatesh Krishnamurthi, Jihad Kaouk, Christopher J Weight, Moshe C Ornstein

Urology· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma.
Kathryn E Beckermann, Neil J Shah, Matthew T Campbell, Naomi B Haas, Ariel Nelson, Moshe C Ornstein

Oncologist· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab.
Moshe C Ornstein, Laeth George, Wei Wei, C Marcela Diaz-Montero, Pat Rayman

Clin Genitourin Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Preferences Among Patients with Renal Cell Carcinoma: Results from a Discrete Choice Experiment.
Moshe C Ornstein, Lisa C Rosenblatt, Xin Yin, Viviana Del Tejo, Sarah B Guttenplan

Patient Prefer Adherence· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes for Metastatic Renal Cell Carcinoma (mRCC) Patients Ineligible for Front-line Clinical Trials.
Nathan Reynolds, Wei Wei, Kimberly Maroli, Amanda Bonham, Amanda Nizam, Moshe C Ornstein

J Kidney Cancer VHL· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PADRES: a phase 2 clinical trial of neoadjuvant axitinib for complex partial nephrectomy.
Kevin Hakimi, Steven C Campbell, Mimi V Nguyen, Nityam Rathi, Luke Wang, Moshe Ornstein

BJU Int· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell Carcinoma.
James Schuster, Iris Y Sheng, Chandana A Reddy, Alok A Khorana, Amanda Nizam, Moshe C Ornstein

Clin Genitourin Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.
Amanda Nizam, Ryan K Rader, Alice Tzeng, Wei Wei, Iris Yeong-Fung Sheng, Moshe C Ornstein

Clin Genitourin Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet A Bilen, Moshe C Ornstein

J Immunother Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor.
Moshe C Ornstein, Laura S Wood

Adv Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting HIF-2 Alpha in Renal Cell Carcinoma.
Ramsha Ahmed, Moshe C Ornstein

Curr Treat Options Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor.
Moshe C Ornstein, Laura S Wood

Adv Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
James Larkin, Mototsugu Oya, Marcella Martignoni, Fiona Thistlethwaite, Paul Nathan, Moshe C Ornstein

Oncologist· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F McDermott, Mehmet A Bilen, Moshe C Ornstein

J Immunother Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Pro.
Steven C Campbell, Moshe C Ornstein, Nityam Rathi

Eur Urol Open Sci· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Landon C Brown, Jason Zhu, Kunal Desai, Emily Kinsey, Chester Kao, Moshe C Ornstein

J Immunother Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F McDermott, Mehmet A Bilen, Moshe Ornstein

J Clin Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors.
Iris Y Sheng, Shilpa Gupta, Chandana A Reddy, Dana Angelini, Pauline Funchain, Moshe C Ornstein

Target Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma.
Oscar Reig Torras, Akhilesh Mishra, Alana Christie, Tiffani McKenzie, Oreoluwa Onabolu, Moshe C Ornstein

Eur Urol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Studying the association between breast cancer and renal cell carcinoma.
Khalid Jazieh, Firas Baidoun, Nataly Torrejon, Zahi Merjaneh, Anas Saad, Moshe Ornstein

Breast Cancer Res Treat· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy.
Iris Y Sheng, Shilpa Gupta, Chandana A Reddy, Dana Angelini, Pauline Funchain, Moshe C Ornstein

Target Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma.
Scott J Dawsey, Moshe C Ornstein

Curr Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis